Meridian Bioscience

Meridian Bioscience, Inc. engages in the development, production, sale, and distribution of diagnostic products. Its platforms include molecular, immunoassay, urea breath, and blood chemistry. It operates through the Diagnostics and Life Science segments. The Diagnostics segment consists of manufacturing operations for infectious disease and blood chemistry products and the sale and distribution of diagnostics products domestically and abroad. The Life Science segment distributes bulk antigens, antibodies, polymerase chain reaction/ quantitative PCR reagents, nucleotides, competent cells, and bioresearch reagents used by researchers, agri-bio companies, and other diagnostic manufacturing companies. The company was founded by William J. Motto in 1976 and is headquartered in Cincinnati, OH.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Meridian Bioscience is an integrated life science company. The Company is engaged in developing, manufacturing, selling, and distributing clinical diagnostic test kits, for certain gastrointestinal, viral, respiratory, and parasitic infectious diseases; the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/ quantitative polymerase chain reaction (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers, and the contract development and manufacture of proteins and other biologicals under cyclic guanosine monophosphate (cGMP) conditions for use by biopharmaceutical and biotechnology companies engaged in research for new drugs and vaccines. The Company operates in three segments: U.S. Diagnostics, European Diagnostics, and Life Science.

CINCINNATI, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the first quarter ended December 31, 2020.

Meridian Bioscience Reports Record Setting First Quarter Fiscal 2021 Operating Results and Raises Full Year Fiscal 2021 Guidance

Meridian (VIVO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Meridian (VIVO) Might Surprise This Earnings Season

Anavex Life Sciences

Axsome Therapeutics

Hologic

Moderna

Novavax

Cassava Sciences Inc

Vaxart

From vaccines to diagnostics, the opportunities in biotechnology are rich for those who do their homework.

Biotech Bonanza: COVID Launches Science at Warp Speed

CINCINNATI, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, today announced that it will increase production capacity of the company's SARS-CoV-2 molecular diagnostic test on its Revogene® platform after receiving a $5.5M award from the National Institute of Health (NIH) Rapid Acceleration of Diagnostics (RADxSM) initiative and an additional grant from JobsOhio.

Meridian Bioscience Expands Production Capacity with Support from NIH, JobsOhio, and the Village of Newtown

Meridian Bioscience's (VIVO) fiscal first-quarter results are likely to reflect strong performance by Life Science business line.

What's in Store for Meridian Bioscience's (VIVO) Q1 Earnings?

CINCINNATI, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today that it has developed a series of innovative and high performing master mixes designed for manufacturing room-temperature stable molecular diagnostic assays that do not require lyophilization. The conventional approach to manufacture room-temperature stable molecular assay is lyophilization, which is expensive, time consuming, and requires expertise and sophisticated equipment. Meridian's new air-dryable master mixes for DNA/RNA detection replace the need for lyophilization with a fast, simple and inexpensive oven-drying procedure.

Meridian's Air-Dryable Master Mixes Replace Lyophilization in the Manufacturing of Molecular Assays

In the latest trading session, Meridian Bioscience (VIVO) closed at $22.10, marking a +1.33% move from the previous day.

Meridian Bioscience (VIVO) Gains As Market Dips: What You Should Know

Meridian Bioscience (VIVO) closed at $22.60 in the latest trading session, marking a -0.88% move from the prior day.

Meridian Bioscience (VIVO) Stock Sinks As Market Gains: What You Should Know

Meridian Bioscience (VIVO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why the Earnings Surprise Streak Could Continue for Meridian Bioscience (VIVO)

CINCINNATI, Jan. 13, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, will report first quarter fiscal 2021 financial results Friday, February 5, 2021.

Meridian Bioscience to Hold First Quarter Fiscal 2021 Financial Results Conference Call on February 5, 2021

Meridian could expand its testing supply windfall in 2021, as the world grapples with containing mutations of the COVID-19 virus. Balance sheet safety, profit margins, revenue growth, and current valuations are better than industry average.

Meridian Bioscience: Benefiting From A Prolonged Pandemic

Teladoc

Arcturus Therapeutics

Arcturus Therapeutics (NASDAQ: ARCT) shares are trading higher on Thursday after Wells Fargo initiated coverage on the stock with an Overweight rating. Arcturus Therapeutics is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases.

Why Teladoc Health, Arcturus And Meridian Are Moving Today

P.A.M. Transportation Services

Ryerson Hld

Scholastic

Schnitzer Steel Industries

We have narrowed down our search to five small cap stocks that have strong growth potential for 2021. These are: SCHL, SCHN, RYI, PTSI, VIVO.

5 Top-Ranked Small Hidden Gems With Strong Upside in 2021

BJ`s Wholesale Club Holdings Inc

Bellicum Pharmaceuticals

Liminal BioSciences

360 Finance Inc - ADR

Vaccinex Inc

Want to try some out-of-the-box approach? Tap five stocks with increasing P/E ratios.

Bet on Rising P/E With These 5 Top-Ranked Stocks

CINCINNATI, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) a provider of diagnostic testing solutions and life science raw materials, announced today its participation in the H. C. Wainright Bioconnect 2021 Virtual Conference. Jack Kenny, Chief Executive Officer, will pre-record a fireside chat that will be available on January 11, 2021.

Meridian Bioscience to Participate in H. C. Wainright Bioconnect 2021 Virtual Conference

Meridian Bioscience (VIVO) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Can Meridian Bioscience (VIVO) Run Higher on Rising Earnings Estimates?

Steel Dynamics

Two Stocks With an Upward Moving Earnings Outlook.

Top Stock Picks for Week of December 28, 2020

McCormick

These stocks offer a mix of speculation and steady growth.

These 3 Stocks Could Turn Your $600 Stimulus Check Into Much More

Aviat Networks

Carriage Services

Lakeland Industries

Piper Sandler Cos

WidePoint

Here are six best-performing stocks with substantial net profit margins that can contribute toward making an enriching portfolio.

6 Top-Rated Stocks With Solid Net Profit Margin

CINCINNATI, Dec. 16, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, today announced that it has been awarded funding in the amount of approximately $1M by the National Institute of Health (NIH) Rapid Acceleration of Diagnostics (RADxSM) initiative, to expedite the launch of the company's SARS-CoV-2 molecular diagnostic test on the Revogene® platform. On December 7, the application for Emergency Use Authorization (EUA) for the Revogene® SARS-CoV-2 assay was submitted to the U.S. Food and Drug Administration (FDA).

Meridian Bioscience receives NIH Award for supporting rapid development of Revogene® molecular test for SARS-CoV-2

Herc Hlds

Systemax

Let's take a look at these six top-ranked stocks with impressive net profit margins for a winning portfolio.

6 Top-Rated Stocks to Bet On With Solid Net Profit Margins

CINCINNATI, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, today announced that it has submitted its application for Emergency Use Authorization (EUA) to the U.S. Food and Drug Administration (FDA) for the company's SARS-CoV-2 molecular diagnostic test on the Revogene® platform.

Meridian Bioscience submits application to FDA for Emergency Use Authorization for SARS-CoV-2 molecular assay

Why Meridian Bioscience (VIVO) Might be Well Poised for a Surge

CINCINNATI, Dec. 03, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today that it has launched an Air-Dryable RT-qPCR Mix, driving innovation in the development of molecular tests with ambient temperature stability. This specialized master mix is designed for air-drying, a cost-effective and easier alternative to lyophilization. With this new product addition, Meridian has the most comprehensive offering of master mixes for developing both DNA and RNA based molecular diagnostic assays at ambient temperature, removing the need for cold chain shipping and storage.

Meridian Launches its Novel Air-Dryable RT-qPCR Mix, Further Decreases Costs and Simplifies Workflows for COVID-19 Molecular Test Manufacturers

CINCINNATI, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) announced today its participation in the Piper Sandler 32nd Annual Virtual Healthcare Conference. Jack Kenny, Chief Executive Officer, and Bryan Baldasare, Executive Vice President and Chief Financial Officer pre-recorded a fireside chat on Tuesday, November 17, 2020.

News for Meridian Bioscience Stock (VIVO)